Regarding circulating biomarkers, the response of AFP at 6 weeks after initiating treatment could be a surrogate biomarker of prognosis in patients with HCC who are receiving atezolizumab + bevacizumab [120]. The gene discussed is AFP; the disease is hepatocellular carcinoma.